Arcellx, Inc. (ACLX) NASDAQ

70.81

-1.81(-2.49%)

Updated at September 08 03:07PM

Currency In USD

Arcellx, Inc.

Address

25 West Watkins Mill Road

Redwood City, MD 20878

United States of America

Phone

240 327 0603

Sector

Healthcare

Industry

Biotechnology

Employees

163

First IPO Date

February 04, 2022

Key Executives

NameTitlePayYear Born
Mr. Rami ElghandourChairman of the Board, Chief Executive Officer & President1.21M1979
Mr. Neeraj P. TeotiaChief Commercial Officer461,9491975
Ms. Michelle Lim GilsonChief Financial Officer785,9921993
Dr. Christopher R. Heery M.D.Chief Medical Officer794,5201980
Ms. Kate AikenChief People Officer0N/A
Ms. Maryam Abdul-Kareem J.D., M.S.General Counsel & Chief Legal Officer0N/A
Ms. Aileen FernandesChief Business Officer0N/A
Mr. Narinderjeet Singh M.S.Chief Technical Officer01972
Ms. Myesha LacyChief Investor & Communications Officer0N/A
Dr. Heba Nowyhed Ph.D.Chief Scientific Officer0N/A

Description

Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.